ArticlePloS one2016

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.

Paul Toren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.